Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer

Liu, Yanlong; Gao, Xu; Jiang, Yang; Zhang, Gan; Sun, Zicheng; Cui, Binbin; Yang, Yanmei

doi:10.1007/s00432-014-1854-5

Cited by 72 publications

(75 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EZH2 is a transcription inhibition factor that inhibits the transcription of multiple cancer suppressor genes and gives rise to the enhancement of invasion and metastasis; it breaks the balance between the promotion and the inhibition of associated genes by migration, which results in the invasion and metastasis of tumors (22). Abnormally high expression of EZH2 may promote cell proliferation: EZH2 gene expression is markedly increased in multiple tumor types including in the prostate, breast, kidney and lung (8). Therefore, it can be concluded that EZH2 is an oncogene.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies revealed that the EZH2 gene participated in cellular growth regulation (6,7). The mechanism underlying the function of EZH2 function was the inhibition of the Wnt signaling pathway in chromatin and the promotion of cell proliferation (7,8). Furthermore, as a transcription inhibition factor, EZH2 influenced the activity of multiple genes at the gene level; most notably, it inhibited tumor metastasis genes (including phosphoinositide, protein kinase B and matrix metalloproteinases), aiding the promotion of infiltration and migration of cancer cells (7,8).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EZH2 inhibition promotes methyl jasmonate‑induced apoptosis of human colorectal cancer through the Wnt/β‑catenin pathway

et al. 2018

View full text Add to dashboard Cite

Abstract. Methyl jasmonate potentially induces the differentiation of human myeloid leukemia cells and inhibits their proliferation; it may induce the differentiation and apoptosis of human lymphocytic leukemia cells, but does not exert a damaging effect on normal lymphocytes. In the present study, the anticancer effect of methyl jasmonate on human colorectal cancer cells was investigated. Cell viability and apoptosis was assessed using a Cell Counting kit-8 assay and flow cytometry, respectively. Methyl jasmonate suppressed cell viability and induced apoptosis in human colorectal cancer cells. Additionally, methyl jasmonate increased the activation of caspase-3, inhibited the expression levels of enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) and the Wnt/β-catenin pathway in human colorectal cancer. Downregulation of EZH2 expression enhanced the anticancer effect of methyl jasmonate on human colorectal cancer cells through suppression of the Wnt/β-catenin pathway. Thus, EZH2 downregulation promotes the anticancer effect of methyl jasmonate by inducing apoptosis in human colorectal cancer cells through the Wnt/β-catenin pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

EZH2 inhibition promotes methyl jasmonate‑induced apoptosis of human colorectal cancer through the Wnt/β‑catenin pathway

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Previous studies of EZH2 mRNA expression based on a resource of tissue samples with follow-up data have provided invaluable information about clinical outcome of cancer patients. [39][40][41] In this study, urinary cf-EZH2 mRNA levels were found to be associated with multifocality and stage of MIBC patients. Based on the optimal cutoff value of cf-EZH2 mRNA that distinguishing the two types of BC, we divided the MIBC patients into two groups, with high and low EZH2 expression.…”

Section: Discussionmentioning

confidence: 52%

“…Previous studies of EZH2 mRNA expression based on a resource of tissue samples with follow‐up data have provided invaluable information about clinical outcome of cancer patients . In this study, urinary cf‐EZH2 mRNA levels were found to be associated with multifocality and stage of MIBC patients.…”

Section: Discussionmentioning

confidence: 60%

Nested quantitative PCR approach for urinary cell‐free EZH2 mRNA and its potential clinical application in bladder cancer

Zhang

Liu²,

Liu

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

EZH2 is overexpressed in bladder cancer (BC) and plays important roles in tumor development and progression. Recent studies show cell free (cf) RNAs released from cancer cells can reflect tissues changes and are stable and detectable in urine. Although conventional quantitative real-time PCR (qPCR) is highly sensitive, low abundances of urinary cf-RNAs usually result in false-negatives. Thus, this study develops a nested qPCR (nqPCR) approach to quantify cf-EZH2 mRNA in urine and further assess its clinical significance for BC. Forty urine samples were first selected to evaluate feasibility of nqPCR. Then, levels of urinary cf-EZH2 mRNA were detected using developed method in an independent cohort of subjects with 91 healthy, 81 cystitis, 169 nonmuscle invasive BC (NMIBC) and 103 muscle-invasive BC (MIBC). In cf-EZH2 mRNA detection, nqPCR method was significantly associated with qPCR, but it could detect more urine samples and increase detection limit three orders of magnitude. Based on nqPCR method, cf-EZH2 mRNA levels have been found to be increased in urine of NMIBC and MIBC patients (p < 0.001). Compared with cytology, cf-EZH2 mRNA showed higher diagnostic ability for MIBC (p < 0.001) while not for NMIBC (p > 0.05). Moreover, it also could distinguish MIBC from NMIBC, with AUC of 0.787. For MIBC patients, high expression of cf-EZH2 mRNA associated with advanced stage and was an independent predictor of reduced disease free survival or overall survival. In conclusion, detection of cf-EZH2 mRNA in urine by nqPCR is a sensitive and noninvasive approach and may be used for diagnosis and prognosis prediction of MIBC.

show abstract

“…In mammals, there are two types of polycomb group complexes, PCR1 and PCR2. The PCR2 complex consists of four core components: Ezh2, Suppressor of Zeta 12 (SUZ12), EED, and retinoblastoma associated protein 46/48 [ 13 ]. Ezh2 with SET domain forms a complex, which catalyzes H3K27me3 and is involved in the silencing of tumor suppressor genes such as Disabled homology2-interaction protein (DAB2IP) (Fig.…”

Section: Role Of Ezh2 In Prostate Cancermentioning

confidence: 99%

Enhancer of Zeste Homology 2 (Ezh2), an Epigenetic Regulator: A Possibility for Prostate Cancer Treatment

Kumar

Stokes

Singh

et al. 2016

Epigenetic Advancements in Cancer

View full text Add to dashboard Cite

Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer

Abstract: High expression of EED, SUZ12 and EZH2 might contribute to the CRC development/progression.

Cited by 72 publications

References 47 publications

EZH2 inhibition promotes methyl jasmonate‑induced apoptosis of human colorectal cancer through the Wnt/β‑catenin pathway

EZH2 inhibition promotes methyl jasmonate‑induced apoptosis of human colorectal cancer through the Wnt/β‑catenin pathway

Nested quantitative PCR approach for urinary cell‐free EZH2 mRNA and its potential clinical application in bladder cancer

Enhancer of Zeste Homology 2 (Ezh2), an Epigenetic Regulator: A Possibility for Prostate Cancer Treatment

Contact Info

Product

Resources

About